US Patent 11401512 Engineered target specific nucleases
Patent 11401512 was granted and assigned to Sangamo Therapeutics on August, 2022 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 11401512 Engineered target specific nucleases
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
